Labeled for this condition
Medicines for multiple sclerosis
23 medicines have an FDA label indicated for multiple sclerosis; 11 are listed from generic labelers and 2 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for multiple sclerosis?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Prednisone | none listed | 45 labelers | $0.0643 per tablet 20 mg tablet | No | No current entry | 10 |
| Dexamethasone | Ozurdex, Maxidex, Hemady | 60 labelers | $0.193 per tablet 4 mg tablet | No | In shortage | 8 |
| Methylprednisolone | Solu-Medrol, Depo-Medrol, Medrol | 35 labelers | $0.121 per tablet 4 mg tablet | No | In shortage | 46 |
| Betamethasone | Celestone, Sernivo, Diprolene | 28 labelers | $0.418 per gram 0.05% cream | No | No current entry | 13 |
| Prednisolone | Orapred, Pred | 25 labelers | $4.72 per mL 1% eye drop | No | No current entry | 9 |
| Dimethyl fumarate | Tecfidera | 19 labelers | $0.467 per capsule 240 mg capsule | No | No current entry | 1 |
| Teriflunomide | Aubagio | 15 labelers | $0.233 per tablet 14 mg tablet | Yes | No current entry | 1 |
| Fingolimod | Tascenso, Gilenya | 21 labelers | $1.58 per capsule 0.5 mg capsule | No | No current entry | 1 |
| Glatiramer | Copaxone, Glatopa | 8 labelers | $86.10 per mL 40 mg/mL syringe | Yes | No current entry | 4 |
| Dalfampridine | Ampyra | 9 labelers | $0.399 per tablet 10 mg tablet | No | No current entry | 0 |
| Interferon beta 1a | Rebif, Avonex | none listed | $1,848.67 per mL 44 mcg/0.5 mL | No | No current entry | 0 |
| Cladribine | Mavenclad | 6 labelers | n/a | Yes | No current entry | 0 |
| Siponimod | Mayzent | none listed | n/a | No | No current entry | 0 |
| Corticotropin | Acthar, Purified | none listed | n/a | No | No current entry | 2 |
| Peginterferon beta 1a | Plegridy | none listed | n/a | No | No current entry | 0 |
| Ponesimod | Ponvory | none listed | n/a | No | No current entry | 0 |
| Alemtuzumab | Lemtrada, Campath | none listed | n/a | Yes | No current entry | 0 |
| Natalizumab | Tyruko, Tysabri | none listed | n/a | Yes | No current entry | 0 |
| Diroximel fumarate | Vumerity | none listed | n/a | No | No current entry | 1 |
| Interferon beta 1b | Betaseron | none listed | $725.97 per kit 0.3 mg kit | No | No current entry | 0 |
| Monomethyl fumarate | Bafiertam | none listed | n/a | No | No current entry | 0 |
| Ofatumumab | Kesimpta | none listed | $24,369.37 per mL 20 mg/0.4 mL pen | No | No current entry | 0 |
| Ublituximab | Briumvi | none listed | n/a | No | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price